ライフサイエンスコーパス: Glasgow outcome scale

1 ry outcomes were all-cause mortality and the Glasgow Outcome Scale.

2 rapies, decompressive craniotomy, or 3-month Glasgow Outcome Scale.

3 ive to detecting changes in outcome than the Glasgow Outcome Scale.

4 er discharge survival and improved discharge Glasgow Outcome Scale.

5 y cerebral autoregulation index predictor of Glasgow Outcome Scale.

6 for an unfavorable outcome according to the Glasgow Outcome Scale.

7 come was determined in all patients with the Glasgow outcome scale.

8 Outcome was assessed using the Glasgow Outcome Scale.

9 good recovery or moderate disability on the Glasgow outcome scale.

10 ral basis for the clinical assessment in the Glasgow Outcome Scale.

11 ivors were assessed after 6 months using the Glasgow outcome scale.

12 Outcome was assessed at 6 months using the Glasgow Outcome Scale.

13 hs after injury was assessed by means of the Glasgow Outcome Scale.

14 el index, the modified Rankin Scale, and the Glasgow Outcome Scale.

15 , 6, and 12 months later with the use of the Glasgow Outcome Scale.

16 ad component only), 0.53 (p < .001); 6-month Glasgow Outcome Scale, -0.26 (p = .006); ICP burden (hou

17 ath, vegetative state, or severe disability (Glasgow Outcome Scale 1-3) after 6 months.

18 Rankin Scale 0-3, Barthel Index 70-100, and Glasgow Outcome Scale 4-5.

19 unfavorable global outcome according to the Glasgow Outcome Scale, a lower score on the Mini-Mental

20 ors were associated with favorable discharge Glasgow Outcome Scale: all operating room cerebral perfu

21 of adherence were associated with favorable Glasgow Outcome Scale among survivors (adjusted hazard r

22 diac arrest using the modified Rankin Scale, Glasgow Outcome Scale, and Barthel Index.

23 gow Coma Scale (GCS), modified Rankin Scale, Glasgow Outcome Scale, and hospital and NCCU lengths of

24 predicted patient outcome measured with the Glasgow Outcome Scale as a continuous outcome (R = 0.82;

25 c brain injury and were classified using the Glasgow Outcome Scale as follows: moderately disabled (n

26 thalamic nuclei in patients assessed by the Glasgow Outcome Scale as moderately disabled (n = 9), se

27 r their effect on outcome as measured by the Glasgow Outcome Scale at 6 months after injury.

28 Outcome was assessed using the Glasgow Outcome Scale at 6 months post-injury.

29 Unfavorable outcome in Glasgow Outcome Scale at 6 months was not associated wit

30 Scores on the extended Glasgow outcome scale at 6 months were fitted to a multi

31 ociated infection rate), length of ICU stay, Glasgow Outcome Scale at 6 months, and risk factors for

32 Lower Glasgow Outcome Scale at hospital discharge and the Univ

33 s (Barthel index, modified Rankin scale, and Glasgow Outcome Scale) at days 30 and 90.

34 Scale Extended = 1) and unfavorable outcome (Glasgow Outcome Scale Extended 1-4).

35 Scale Extended was dichotomized into death (Glasgow Outcome Scale Extended = 1) and unfavorable outc

36 (P = 0.076) and at 1 y (P = 0.051) and with Glasgow Outcome Scale Extended at discharge (P = 0.091)

37 The Glasgow Outcome Scale Extended was dichotomized into dea

38 SF-12, Glasgow Outcome Scale-Extended (GOS-E), pain scores, and

39 ma Scale score to predict performance on the Glasgow Outcome Scale-Extended 10-40 months after injury

40 hed patients with TBI who had good outcomes (Glasgow Outcome Scale-Extended GOS-E, 7-8) (AUC = 0.663

41 ve, 0.04; p = 0.28) for predicting patients' Glasgow Outcome Scale-Extended score.

42 an Dysfunction Scale score, and poor 6-month Glasgow Outcome Scale-Extended score.

43 fixation remained a significant predictor of Glasgow Outcome Scale-Extended scores (beta, -0.29; p <

44 Rates of favorable improvement for the Glasgow Outcome Scale-Extended were 35.4% in the citicol

45 ) of respondents had a good recovery via the Glasgow Outcome Scale-Extended>/=7 (41.1% if patients wh

46 24 months after injury to measure function (Glasgow Outcome Scale-Extended) and return to work/study

47 Predictors of 12-month functional (Glasgow Outcome Scale-Extended) outcomes after blunt maj

48 ctured and validated measures of disability (Glasgow Outcome Scale-Extended), psychological well bein

49 ed-up via telephone interview, including the Glasgow Outcome Scale-Extended, the 12-item short form h

50 Outcome was measured at 6 months using the Glasgow Outcome Scale-Extended.

51 ient characteristics, treatment, and 6-month Glasgow Outcome Scale-Extended.

52 sociated with better 6-month outcomes on the Glasgow Outcome Scale-Extended.

53 oregulation index predictors of mortality or Glasgow Outcome Scale for patients with traumatic brain

54 idal neurons with a more severe score on the Glasgow Outcome Scale from all four cortical regions, wi

55 of patients with a favorable outcome on the Glasgow Outcome Scale (good recovery or moderate disabil

56 function at 3 months after injury using the Glasgow outcome scale (GOS) and the GOS-extended pediatr

57 The primary endpoint was the Glasgow Outcome Scale (GOS) score at 3 months after brai

58 functional outcome at 90 days, defined as a Glasgow Outcome Scale (GOS) score of 5 (range, 1 to 5, w

59 kin scale (mRS), the Barthel index (BI), the Glasgow outcome scale (GOS), and the stroke impact scale

60 at hospital discharge was evaluated with the Glasgow Outcome Scale (GOS).

61 imary outcome was the rating on the Extended Glasgow Outcome Scale (GOS-E) (an 8-point scale, ranging

62 RI features that were predictive of Extended Glasgow Outcome Scale (GOS-E) at 3 months postinjury.

63 stic regression on the dichotomized Extended Glasgow Outcome Scale (GOS-E) at 5 years as a measure of

64 rimary outcome was the score on the Extended Glasgow Outcome Scale (GOS-E; range, 1 to 8, with lower

65 functional outcome (dichotomizations of the Glasgow Outcome Scale [GOS]).

66 nth neurologic outcome based on the Extended Glasgow Outcome Scale (GOSE) (dichotomized as >4 or </=4

67 nfavourable) outcome of the 8 point Extended Glasgow Outcome Scale (GOSE) obtained by questionnaires

68 changes in cortical neuron population across Glasgow Outcome Scale groups between diffuse axonal inju

69 en remaining neurons usually occurred across Glasgow Outcome Scale groups.

70 heir size and nearest neighbour index across Glasgow Outcome Scale groups.

71 differences across groups classified by the Glasgow Outcome Scale in intracranial pressure, pressure

72 We used the eight-point Glasgow outcome scale obtained by postal questionnaires

73 ts versus 5 placebo patients survived with a Glasgow Outcome Scale of 4 or 5.

74 le outcomes (death or modified Rankin Scale, Glasgow Outcome Scale, or World Federation of Neurosurge

75 e of the patients, assessed using either the Glasgow outcome scale (P = 0.005, n = 17) or the disabil

76 at the time of hospital discharge, using the Glasgow Outcome Scale (P<0.01).

77 001) and patient outcome (as assessed by the Glasgow Outcome Scale) (p = .05).

78 ciated with an increased risk of unfavorable Glasgow Outcome Scale (risk ratio, 2.46; 95% CI, 1.06-5.

79 95% CI, 1.01-3.15; I = 43%) and unfavorable Glasgow Outcome Scale (risk ratio, 2.49; 95% CI, 1.72-3.

80 dicting delayed cerebral infarctions or poor Glasgow Outcome Scale score (1-3).

81 .99-3.21; four studies) and no difference in Glasgow Outcome Scale score (mean difference, -0.45; 95%

82 complete testing; only 3.9% of Good Outcome (Glasgow Outcome Scale score = 1) patients were untested,

83 Primary outcome measure was the Glasgow Outcome Scale score at 3 months (a score of 5 [f

84 of the stratified dichotomy of the Extended Glasgow Outcome Scale score at 6 months after injury.

85 The primary efficacy end point was the Glasgow Outcome Scale score at 6 months after the injury

86 The primary outcome was the Glasgow outcome scale score at 6 months.

87 Glasgow Outcome Scale score dichotomized as favorable (g

88 Poor outcome, defined as Glasgow Outcome Scale Score of 3-5 at 2 months or discha

89 2 criterion was survival at 6 months with a Glasgow Outcome Scale score of 4 or 5 (group 2A) or 3 (g

90 Good neurologic outcome (Glasgow Outcome Scale score of 4 or 5) was determined at

91 noid hemorrhage patients, as assessed by the Glasgow Outcome Scale score or other neurological and fu

92 ents, therapies targeting edema, and 3-month Glasgow Outcome Scale score.

93 Main outcomes were discharge survival and Glasgow Outcome Scale score.

94 tested, compared with 38.6% of patients with Glasgow Outcome Scale scores of 3 and 4.

95 found among the QOLIBRI-OS and the extended glasgow outcome scale, short-form-36, and hospital anxie

96 at admission was 7 (range 3-14), and median Glasgow Outcome Scale was 3 (range 1-5).

97 mission Glasgow Coma Scale was 6, the median Glasgow Outcome Scale was 3, and the mortality at 6 mont

98 No significant differences were found when Glasgow Outcome Scale was analyzed according to the two

99 However, in the motor cortex a more severe Glasgow Outcome Scale was associated with an increased d

100 re, baseline Glasgow Coma Scale and 6 months Glasgow Outcome Scale were recorded.

101 onth outcome (evaluated using a dichotomized Glasgow Outcome Scale) were also introduced in multivari

102 y and functional outcome, as measured by the Glasgow Outcome Scale, were determined.